Literature DB >> 11049097

Validity of the hospital discharge diagnosis in epidemiologic studies of biliopancreatic pathology. PANKRAS II Study Group.

M Porta1, S Costafreda, N Malats, L Guarner, M Soler, J M Gubern, E García-Olivares, M Andreu, A Salas, J M Corominas, J Alguacil, A Carrato, J Rifà, F X Real.   

Abstract

BACKGROUND: The aim was to analyse the magnitude, direction and predictors of change in the main hospital discharge diagnosis (HDD) after a clinical expert review, among patients included in a multicentre molecular epidemiologic study of biliopancreatic diseases.
METHODS: A total of 602 patients with a suspicion diagnosis of pancreas cancer (PC), cancer of the extrahepatic biliary system (CEBS) or benign biliopancreatic pathologies (BPP) were prospectively recruited at five general hospitals. A structured form was used to collect information from medical records. A panel of experts revised all diagnostic information and established the main clinicopathological diagnosis (CPD) by consensus.
RESULTS: Of the 204 cases with a HDD of PC, 176 (86%) were deemed to have a CPD of PC, eight of CEBS, twelve a neoplasm of different origin, four BPP and four syndromic diagnoses. Thus, 28 cases (14%) were false positives. Of the 129 patients with a HDD of CEBS, 15 (12%) were false positives. Nine of the 396 cases with a HDD of non-PC (2%) had a CPD of PC (false negatives), whilst 14 of 471 patients with a HDD of non-CEBS (3%) were deemed to have CEBS. Overall, sensitivity and specificity of HDD for PC were, respectively, 95 and 93%, and for CEBS, 89 and 97%. Cytohistological confirmation and laparotomy were independent predictors of diagnostic change.
CONCLUSIONS: Validity of the HDD was high, but its association with some clinical variables suggests that sole reliance on HDD can significantly bias results, and highlights the need to review all HDDs. Alternatively, only patients at high risk of misdiagnosis could be reviewed: primarily, those lacking a cytohistological diagnosis or a laparotomy. No exclusions appear warranted solely on the basis of age, gender or tumour spread.

Entities:  

Mesh:

Year:  2000        PMID: 11049097     DOI: 10.1023/a:1007692408457

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  27 in total

Review 1.  Pancreatic and biliary endoscopy.

Authors:  W R Brugge; J Van Dam
Journal:  N Engl J Med       Date:  1999-12-09       Impact factor: 91.245

2.  Epidemiology: bridges over (and across) roaring levels.

Authors:  M Porta; C Alvarez-Dardet
Journal:  J Epidemiol Community Health       Date:  1998-10       Impact factor: 3.710

3.  Association between coffee drinking and K-ras mutations in exocrine pancreatic cancer. PANKRAS II Study Group.

Authors:  M Porta; N Malats; L Guarner; A Carrato; J Rifà; A Salas; J M Corominas; M Andreu; F X Real
Journal:  J Epidemiol Community Health       Date:  1999-11       Impact factor: 3.710

4.  Workup of a patient with a mass in the head of the pancreas.

Authors:  W M Steinberg; J Barkin; E L Bradley; E DiMagno; P Layer
Journal:  Pancreas       Date:  1998-07       Impact factor: 3.327

Review 5.  Pancreatic adenocarcinoma: an update.

Authors:  H P Tan; J Smith; C A Garberoglio
Journal:  J Am Coll Surg       Date:  1996-08       Impact factor: 6.113

Review 6.  Pancreatic carcinoma.

Authors:  S Rosewicz; B Wiedenmann
Journal:  Lancet       Date:  1997-02-15       Impact factor: 79.321

Review 7.  Diagnosis of pancreatic carcinoma. Imaging techniques and tumor markers.

Authors:  C Niederau; J H Grendell
Journal:  Pancreas       Date:  1992       Impact factor: 3.327

8.  Occupational exposures and pancreatic cancer: a meta-analysis.

Authors:  I A Ojajärvi; T J Partanen; A Ahlbom; P Boffetta; T Hakulinen; N Jourenkova; T P Kauppinen; M Kogevinas; M Porta; H U Vainio; E Weiderpass; C H Wesseling
Journal:  Occup Environ Med       Date:  2000-05       Impact factor: 4.402

Review 9.  Occurrence, trends and environment etiology of pancreatic cancer.

Authors:  E Weiderpass; T Partanen; R Kaaks; H Vainio; M Porta; T Kauppinen; A Ojajärvi; P Boffetta; N Malats
Journal:  Scand J Work Environ Health       Date:  1998-06       Impact factor: 5.024

10.  Autopsy diagnoses of malignant neoplasms: how often are clinical diagnoses incorrect?

Authors:  E C Burton; D A Troxclair; W P Newman
Journal:  JAMA       Date:  1998-10-14       Impact factor: 56.272

View more
  11 in total

1.  Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage.

Authors:  Miquel Porta; Xavier Fabregat; Núria Malats; Luisa Guarner; Alfredo Carrato; Ana de Miguel; Laura Ruiz; Manuel Jariod; Sergi Costafreda; Susana Coll; Juan Alguacil; Josep M Corominas; Ricard Solà; Antonio Salas; Francisco X Real
Journal:  Clin Transl Oncol       Date:  2005-06       Impact factor: 3.405

2.  Timing of blood extraction in epidemiologic and proteomic studies: results and proposals from the PANKRAS II Study.

Authors:  Miquel Porta; José Pumarega; Olga Ferrer-Armengou; Tomàs López; Joan Alguacil; Núria Malats; Esteve Fernàndez
Journal:  Eur J Epidemiol       Date:  2007-07-18       Impact factor: 8.082

3.  Estimating dietary intakes from a brief questionnaire: A simulation study of reliability in a molecular epidemiologic study of pancreatic and biliary diseases.

Authors:  Michelle A Mendez; Jesús Vioque; Miquel Porta; Eva Morales; Tomàs López; Núria Malats; Marta Crous; Luis I Gómez
Journal:  Eur J Epidemiol       Date:  2006-07-08       Impact factor: 8.082

4.  Keratin 8 sequence variants in patients with pancreatitis and pancreatic cancer.

Authors:  Matthias Treiber; Hans-Ulrich Schulz; Olfert Landt; Joost P H Drenth; Carlo Castellani; Francisco X Real; Nejat Akar; Rudolf W Ammann; Mario Bargetzi; Eesh Bhatia; Andrew Glenn Demaine; Cinzia Battagia; Andrew Kingsnorth; Derek O'Reilly; Kaspar Truninger; Monika Koudova; Julius Spicak; Milos Cerny; Hans-Jürgen Menzel; Pedro Moral; Pier Franco Pignatti; Maria Grazia Romanelli; Olga Rickards; Gian Franco De Stefano; Narcis Octavian Zarnescu; Gourdas Choudhuri; Sadiq S Sikora; Jan B M J Jansen; Frank Ulrich Weiss; Matthias Pietschmann; Niels Teich; Thomas M Gress; Johann Ockenga; Hartmut Schmidt; Andreas Kage; Juliane Halangk; Jonas Rosendahl; David Alexander Groneberg; Renate Nickel; Heiko Witt
Journal:  J Mol Med (Berl)       Date:  2006-10-13       Impact factor: 4.599

5.  Cystic fibrosis transmembrane regulator (CFTR) DeltaF508 mutation and 5T allele in patients with chronic pancreatitis and exocrine pancreatic cancer. PANKRAS II Study Group.

Authors:  N Malats; T Casals; M Porta; L Guarner; X Estivill; F X Real
Journal:  Gut       Date:  2001-01       Impact factor: 23.059

6.  Clinical validity of detecting K-ras mutations for the diagnosis of exocrine pancreatic cancer: a prospective study in a clinically-relevant spectrum of patients.

Authors:  Lucy A Parker; Miquel Porta; Blanca Lumbreras; Tomàs López; Luisa Guarner; Ildefonso Hernández-Aguado; Alfredo Carrato; Josep M Corominas; Juli Rifà; Esteve Fernandez; Joan Alguacil; Núria Malats; Francisco X Real
Journal:  Eur J Epidemiol       Date:  2011-02-06       Impact factor: 8.082

7.  Family history of cancer and germline BRCA2 mutations in sporadic exocrine pancreatic cancer.

Authors:  F X Real; N Malats; G Lesca; M Porta; S Chopin; G M Lenoir; O Sinilnikova
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

8.  Concentrations of trace elements and KRAS mutations in pancreatic ductal adenocarcinoma.

Authors:  Álvaro Gómez-Tomás; José Pumarega; Juan Alguacil; André F S Amaral; Núria Malats; Natàlia Pallarès; Magda Gasull; Miquel Porta
Journal:  Environ Mol Mutagen       Date:  2019-05-23       Impact factor: 3.216

9.  Influence of KRAS mutations, persistent organic pollutants, and trace elements on survival from pancreatic ductal adenocarcinoma.

Authors:  Miquel Porta; José Pumarega; André F S Amaral; Jeanine M Genkinger; Judit Camargo; Lorelei Mucci; Juan Alguacil; Magda Gasull; Xuehong Zhang; Eva Morales; Mar Iglesias; Shuji Ogino; Lawrence S Engel
Journal:  Environ Res       Date:  2020-06-11       Impact factor: 6.498

10.  A Multicenter Trial Defining a Serum Protein Signature Associated with Pancreatic Ductal Adenocarcinoma.

Authors:  Anna S Gerdtsson; Núria Malats; Anna Säll; Francisco X Real; Miquel Porta; Petter Skoog; Helena Persson; Christer Wingren; Carl A K Borrebaeck
Journal:  Int J Proteomics       Date:  2015-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.